Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Function of Cholangiocytes in chronic liver diseases

Project description

Exploring the role of cholangiocytes in liver disease

The rates of chronic liver diseases such as metabolic dysfunction associated steatotic liver disease (MASLD) and its severe form, metabolic dysfunction associated steatohepatatis (MASH), are rising rapidly, yet lack effective treatments. While cholangiocytes (the cells lining the biliary tree) are key to bile drainage and liver regeneration, their role in disease progression and cancer remains underexplored. The ERC-funded FunChol project seeks to address this gap by combining cutting-edge research methods, including organoids, single cell analyses and preclinical models, to unravel how cholangiocytes drive tissue repair or exacerbate disease. Focusing on the mechanisms of cholangiocyte activation, plasticity and transformation, FunChol aims to uncover therapeutic targets to promote liver regeneration and combat disease progression, offering hope for treatments.

Objective

Cholangiocytes are the mCholangiocytes are the main cell type lining the epithelium of the biliary tree, a network of conduits which drain the liver from bile produced by hepatocytes. While the role of cholangiocytes have been broadly studied in the context of cholangiopathies, their role in chronic liver disease affecting hepatocytes is often overlooked despite growing evidence that they play a central role in disease progression, regeneration, and cancer. Thus, understanding the mechanisms controlling the regenerative potential of cholangiocytes is essential to develop new therapies promoting tissue repair or blocking tumour formation. However, the study of these mechanisms has been restricted by technical and conceptual barriers especially in human.
Here, we propose to bypass these limitations by developing an innovative program of research combining functional experiments in organoids, single cell analyses on human primary tissue and preclinical studies in animal models. We will use this approach to specifically address the role of cholangiocytes in chronic liver disease. More precisely, we aim to uncover the mechanisms driving cholangiocytes activation, plasticity and transformation. Importantly, we hypothesise that these different processes are interlinked and share common factors. The FunChol program will systematically address these questions in the context of Non-Alcoholic Fatty Liver Disease (NAFLD). This chronic disease and its progressive form Non-alcoholic Steatohepatitis (NASH) represent the most rapidly rising cause of liver cirrhosis worldwide and there is currently no therapy for this major health care challenge.
Overall, this multidisciplinary proposal will reveal the molecular interplays by which liver injuries can affect cholangiocytes and how in turn cholangiocytes react to improve tissue repair or to aggravate disease. This research will pave the way for the development of new therapeutics controlling regeneration to limit disease progression.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC - HORIZON ERC Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2023-ADG

See all projects funded under this call

Host institution

CHARITE - UNIVERSITAETSMEDIZIN BERLIN
Net EU contribution
€ 2 499 289,00
Address
Chariteplatz 1
10117 Berlin
Germany
Region
Berlin Berlin Berlin
Activity type
Higher or Secondary Education Establishments
Links
Total cost
€ 2 499 289,00

Beneficiaries (1)